Our
Story

Our team started together at the University of Antwerp in 2019. We combined our diverse backgrounds across cancer research, engineering, and business to tackle urgent challenges in oncology and improve patient lives. In 2023, we officially incorporated Orbits Oncology in the USA.

Our mission is to help oncologists match the right therapies to the right cancer patients, by unlocking the predictive potential of patient-derived organoids with our AI-powered computational platform. Our technology will help biopharma stratify patients for clinical trials and oncologists personalize treatment strategies for their patients.